<DOC>
	<DOCNO>NCT00943293</DOCNO>
	<brief_summary>This clinical research study design evaluate whether administration vaccine patient transplant consist minor histocompatibility antigen ( mHag peptide ) mix G-CSF ( drug intend stimulate immune system ) stimulate increase graft versus leukemia ( GVL ) responses without cause graft-versus-host disease ( GVHD ) .</brief_summary>
	<brief_title>Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation Advanced Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Relapsed refractory acute myelogenous lymphoid leukemia . Acute myeloid lymphocytic leukemia first remission highrisk recurrence . Chronic myelogenous leukemia accelerate phase blastcrisis . Chronic myelogenous leukemia second subsequent chronic phase Recurrent refractory malignant lymphoma Hodgkin 's disease Multiple myeloma high risk disease recurrence . Chronic lymphocytic leukemia , relapse poor prognostic feature . Myeloproliferative disorder ( polycythemia vera , myelofibrosis ) poor prognostic feature . Clinical progression . Contraindications vaccination .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>GVHD</keyword>
</DOC>